KirenJeanKresa-ReahlMD

Neurology • Portland, OR

Physician

Join to view full profile

Dr. Kresa-Reahl is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Kresa-Reahl's full profile

Already have an account?

Office
9427 SW Barnes Rd
Ste 595
Portland, OR 97225
Phone+1 503-216-1060

Fax+1 503-216-1066

Education & Training

MedStar Health/Georgetown-Washington Hospital CenterInternship, Internal Medicine, 1991 - 1992
Georgetown University School of MedicineClass of 1991

Certifications & Licensure

OR State Medical License 2010 - 2023
WV State Medical License 1996 - 2012
DC State Medical License 1995 - 1997

Clinical Trials

Measurement of Relaxin Peptide in Multiple Sclerosis (MS) Start of enrollment: 2013 Sep 20
Completed

Publications & Presentations

PubMed

3 citations
Treatment Patterns and Unmet Need for Patients with Progressive Multiple Sclerosis in the United States: Survey Results from 2016 to 2021.
Crystal Watson, Dhanalakshmi Thirumalai, Arie Barlev, Eddie Jones, Sasha Bogdanovich
Neurology and Therapy. 2023-12-01
5 citations
Results from Patient Interviews on Fatigue in Progressive Multiple Sclerosis and Evaluation of Fatigue Patient-Reported Outcome (PRO) Instruments.
Crystal Watson, Kayla Scippa, Arie Barlev, Kiren Kresa-Reahl, Jason C Cole
Neurology and Therapy. 2022-06-01
5 citations
Effectiveness of Dimethyl Fumarate in Patients With Relapsing Multiple Sclerosis Switching After Suboptimal Response to Glatiramer Acetate, Including Patients With Ear...
Pavle Repovic, Derrick Robertson, Kiren Kresa-Reahl, Stanley Cohan, Ray Su
Neurology and Therapy. 2021-06-01

Press Mentions

Atara Biotherapeutics Presents New MRI and Updated Open-Label Extension Data from Phase 1 Study of ATA188 in Progressive Multiple Sclerosis at ECTRIMS 2022October 26th, 2022